Clinical Trials Browser

Phase 3 × Endometrial Neoplasms × 30 days × Clear all

NCT05256225 2026-05-27

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Phase 3 Recruiting

360 enrolled

Gynecologic

Neoplasms, Endometrial Neoplasms

NCT07198074 2026-05-27

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Phase 3 Recruiting

255 enrolled

Gynecologic

Endometrial Neoplasms

NCT07286331 2026-05-27

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

Phase 3 Not yet recruiting

600 enrolled

Gynecologic

Endometrial Neoplasms

NCT06952504 2026-05-22

TroFuse-033

Phase 3 Recruiting

1,123 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06340568 2026-05-20

Fern-EC-01

Phase 3 Recruiting

480 enrolled

Gynecologic

Endometrial Neoplasms

NCT07044336 2026-05-20

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Phase 3 Recruiting

700 enrolled

Gynecologic

Neoplasm Metastasis, Uterine Neoplasms, Endometrial Neoplasms

NCT07578649 2026-05-19

Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

Phase 3 Not yet recruiting

600 enrolled

Gynecologic

Endometrial Neoplasms

NCT06989112 2026-05-06

DE-01

Phase 3 Recruiting

600 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT07166094 2026-05-06

RAINFOL-03

Phase 3 Recruiting

660 enrolled

Gynecologic

Recurrence, Endometrial Neoplasms

NCT05173987 2026-05-05

KEYNOTE-C93

Phase 3 Active not recruiting

280 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3 Active not recruiting

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms